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Abstract
To better understand hepatitis C virus (HCV) epidemiology in Punjab state, India, we esti-
mated the distribution of HCV antibody positivity (anti-HCV+) using a 2013–2014 HCV
household seroprevalence survey. Household anti-HCV+ clustering was investigated (a) by
individual-level multivariable logistic regression, and (b) comparing the observed frequency
of households with multiple anti-HCV+ persons against the expected, simulated frequency
assuming anti-HCV+ persons are randomly distributed. Village/ward-level clustering was
investigated similarly. We estimated household-level associations between exposures and
the number of anti-HCV+ members in a household (N = 1593 households) using multivari-
able ordered logistic regression. Anti-HCV+ prevalence was 3.6% (95% confidence interval
3.0–4.2%). Individual-level regression (N = 5543 participants) found an odds ratio of 3.19
(2.25–4.50) for someone being anti-HCV+ if another household member was anti-HCV+.
Thirty households surveyed had ⩾2 anti-HCV+ members, whereas 0/1000 (P < 0.001) simu-
lations had ⩾30 such households. Excess village-level clustering was evident: 10 villages had
⩾6 anti-HCV+ members, occurring in 31/1000 simulations (P = 0.031). The household-level
model indicated the number of household members, living in southern Punjab, lower socio-
economic score, and a higher proportion having ever used opium/bhuki were associated with
a household’s number of anti-HCV+ members. Anti-HCV+ clusters within households and
villages in Punjab, India. These data should be used to inform screening efforts.
Introduction
The World Health Organization (WHO) has set global targets for 2030 to reduce new infec-
tions of hepatitis C virus (HCV) by 80%, and HCV-related deaths by 65% of the estimated
burden in 2015 [1]. In 2015, an estimated 71 million people were living with HCV infection,
and 400 000 people die annually of HCV-related complications, mainly end-stage liver disease
and liver cancer [2]. Direct-acting antivirals (DAAs) have greatly simplified treatment for HCV
infection due to ease of administration (all oral regimens), minimal side-effects and high
effectiveness [3]. A better understanding of the risk factors driving historical HCV transmis-
sion can support targeted screening and linkage to care, which are needed to reach the WHO
targets [4].
The global HCV burden is unevenly distributed; half of all HCV-infected individuals reside
in six countries, one being India [5]. India’s overall HCV prevalence is an estimated 1%, which
is around the global average. However, as India’s population is 1.3 billion, the country contains
approximately 10 million people living with HCV [6]. Despite a recent systematic review [7],
the Indian HCV burden is poorly described because of a paucity of community-level data [7].
India produces the bulk of the world’s generic licensed DAAs; therefore, prices are lower
than for most countries even after recent price reductions elsewhere [8], reducing an obstacle
to treatment access [9]. In 2016, the Indian state of Punjab, which has a population of almost
30 million people [10], launched a programme to provide treatment free of charge [11].
During 2013–2014, a population-based serosurvey was conducted in Punjab finding an
overall anti-HCV prevalence of 3.6% and an HCV ribonucleic acid (RNA) prevalence of
2.6% [12]. This serosurvey collected demographic data and information on other exposures
possibly associated with HCV [12], identifying associations with the number of blood transfu-
sions received, and the type of practitioner that administered the last medical injection [12].
However, the findings did not account for all possible causes of infection, such as risks asso-
ciated with having been incarcerated [13]. Additionally, no previous study in Punjab, India,
has investigated how HCV is distributed among households.
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An understanding of the epidemiology of HCV in Punjab can
guide prevention efforts and improve the effectiveness of testing
and treatment strategies. The methods outlined for this analysis
may be useful for other settings with HCV epidemics that are
not concentrated among a specific subgroup of population, such
as people who inject drugs (PWID). Understanding how HCV
infection is distributed among households or communities can
inform screening efforts, resulting in the more effective use of
resources, contributing to successful HCV elimination in
Punjab. We aim to investigate the distribution and clustering of
HCV prevalence within Punjab, India.
Methods
Data
This analysis uses data from a cross-sectional seroprevalence sur-
vey conducted in Punjab state, India, 2013–2014, described previ-
ously [12]. Briefly, the study aimed to estimate HCV antibody
(anti-HCV) and viremia prevalence among Punjab residents aged
⩾5 years. The survey included a questionnaire collecting demo-
graphic, economic, medical, risk factor and lifestyle information.
Participants were tested for anti-HCV and those positive for
anti-HCV were tested for HCV RNA by the polymerase-chain
reaction. The study employed a multi-stage stratified cluster sam-
pling design, weighted to the 2011 Punjab Census [10]. All persons
aged ⩾5 years in a selected household were eligible to participate.
Questionnaires were administered confidentially by trained
survey teams via face-to-face interviews for each individual.
After each interview’s completion, a blood sample was obtained
from consenting participants and tested for anti-HCV (Vitros
Immunodiagnostic Anti-HCV, Johnson and Johnson Co., New
Brunswick, NJ, USA). Those testing positive for anti-HCV are
henceforth referred to as anti-HCV+.
The study protocol received approval from the Dayanand
Medical College, Ludhiana, Institutional Review Board, and an
ethical review committee from the Merck Investigator Initiated
Study Protocol-Review Committee. Written consent was obtained
for each participant. Confidentiality was strictly adhered to.
Participation was voluntary; participants aged 5–17 years pro-
vided assent in addition to informed parental/guardian consent.
Variables considered in regression models
Demographic and geographic risk factors
The following characteristics were investigated for association
with anti-HCV positivity: age, sex, rural/urban status and
north/south residence in Punjab. The districts from the south
Punjab included in the study were Muktsar, Moga, Ludhiana,
Sangrur and Mansa; the northern districts were Amritsar,
Jalandhar, Tam Taran, Gurdaspur and Hoshiarpur. The north/
south analysis was included because previous investigations
demonstrated prevalences varied by district (Supplementary
Fig. S1 [12]); and geographical north/south could be generalised
to other provinces not surveyed.
Socio-economic status
Previous studies suggest low socio-economic status (S-ES) is asso-
ciated with increased HCV infection risk from healthcare expo-
sures, such as re-use of syringes [14], which is a common
practice in neighbouring Pakistan and has also been identified
as a risk factor associated with increased odds of HCV in
Punjab, India [15]. A combined, continuous S-ES score variable
was created to increase power and better capture S-ES than indi-
vidual variables.
The following socio-economic indicators were included in
the S-ES score variable: household income in rupees (⩽10 000,
10 001–20 000, 20 001–50 000, >50 000; 10 000 rupees is around
US$140), whether their residence was a kacha (a flimsy construc-
tion) or a pucca (more solid), whether their source of water comes
from a tube well, their educational level (none/primary, middle/
secondary, graduate) and whether their last healthcare provider
used was certified (vs. an uncertified/alternative healthcare pro-
vider – self-reported).
The S-ES variable was scored on a scale of 0–7 as follows: one
point for a household income of 10 001–20 000 rupees and two
points for a household income of >20 000 rupees; one point for
a pucca residence; one point for not using a tube well for water;
one point for completion of middle/secondary school or two
points for completing graduate education; one point for receiving
healthcare from a certified healthcare provider.
When calculating the probabilities that screening would yield a
positive anti-HCV test, we dichotomise the S-ES score into low
(⩽3) and high (>3), chosen as the mid-point of the scale.
Medical risk factors
Medically-associated risk factors possibly associated with HCV
prevalence were: ever had surgery, ever had an invasive medical
procedure, ever had a dental procedure, receipt of a medical injec-
tion in the previous 6 months, ever received a streptomycin injec-
tion for tuberculosis, ever received a blood transfusion and ever
been hospitalised.
The combination risk of medical interventions was estimated
on a scale scored from 0 to 7, allocating one point for each med-
ical risk the participant had ever been exposed to: surgery, an
invasive medical procedure, a dental procedure, a medical injec-
tion in the last 6 months, a streptomycin injection, a blood trans-
fusion, hospitalisation.
Social and other risk factors
Social risk factors (ever had a tattoo, shaving by a barber (as
opposed to at home), ever had a body piercing) and other risk fac-
tors (ever been incarcerated and ever had a motor accident) could
also be associated with HCV prevalence.
Injection drug use (IDU) is considered a driver of HCV trans-
mission in Punjab [16]. PWID have a high HCV prevalence [17].
However, only five subjects (0.1%) surveyed admitted to having
ever injected drugs, a percentage similar to the estimated preva-
lence of current IDU in Punjab [18]. The prevalence of those cur-
rently injecting drugs should be much lower than of ever
injecting. Our survey proportion of ever injectors likely represents
an underestimate of the actual prevalence. A report from 2008
linked smoking traditional, plant-based drugs to IDU [19]. We
examined other drug exposures/behaviours to investigate using
them as proxy measures of IDU. The exposures included: ever
used opium or bhuki (an intoxicating wild grass that is ingested
[20]), ever drank alcohol and ever smoked tobacco.
Clustering of anti-HCV+ prevalence by household and ward/
village
Individual-level analyses
For individual-level analyses, study subjects were stratified by
urban/rural residence, defined by the 2011 Punjab Census [10],
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and weighted by population sizes of the wards (areas within cities)
and villages and clustered by household. Logistic regression was
used to estimate the associations between S-ES score and
anti-HCV status, and medical risk score and anti-HCV status,
both overall and stratified by rural/urban setting.
An individual-level logistic regression was also used to esti-
mate odds ratios (ORs) and adjusted odds ratios (aORs) for
anti-HCV positivity by various characteristics and risk factors,
including a variable of whether another household member was
positive for HCV antibodies. This analysis was repeated with
HCV RNA positivity as the endpoint.
Simulation analyses
To further investigate whether anti-HCV+ persons clustered
within households, the observed frequencies of households con-
taining multiple anti-HCV+ members were compared with the
expected number from simulated data. This simulation assumed
anti-HCV+ persons were randomly distributed with a Binomial
distribution with a mean equal to the proportion of anti-HCV+
cases in the unweighted survey data. Using the same household
structure as found in the survey, 1000 simulations were per-
formed, accounting for the varying urban/rural prevalences. We
assumed the number of household members surveyed was a
proxy for the actual number of individuals living in the house-
hold. This simulation method was repeated for analyses investi-
gating clustering of anti-HCV+ persons within the village/ward
level.
Household-level analyses
Household characteristics were tabulated by the number of
anti-HCV+ members (0, 1 and ⩾2). Ordered logistic regression
models were used to estimate associations between each expos-
ure/characteristic and the number of anti-HCV+ members in a
household (0, 1 or ⩾2), adjusting for the number of household
members, as households with more members have a greater prob-
ability of containing anti-HCV+ household member(s). The
exposure/characteristics that were associated (P < 0.05) with
anti-HCV+ household members (when only adjusted for the
number of household members) were then included in an ordered
logistic regression backwards elimination model. The S-ES score
variable, rather than its individual components (e.g. household
income), was included in the backwards elimination model, to
increase power. A likelihood-ratio test of proportionality of
odds across response categories was performed to test the multi-
variable ordered logistic regression’s assumption of proportional
odds.
Results
There were 5543 eligible participants with available HCV testing
results who completed the survey, described previously [12].
Briefly, 62% of the surveyed population lived in rural areas,
54% were women and the median age was 35 years (interquartile
range (IQR): 21–50). The overall anti-HCV prevalence was 3.6%
(95% confidence interval (95% CI) 3.0–4.2%) and was higher in
rural areas, 4.7% (95% CI 3.8–5.7%), than urban areas, 1.6%
(95% CI 1.1–2.2%). Anti-HCV prevalence varied by district
(Supplementary Fig. S1) and was higher in the south (4.7%
(95% CI 4.0–5.5%)) than the north (2.0% (95% CI 1.4–2.6%)).
The number of members surveyed in each of the 1593 house-
holds was 1, 2, 3, 4 and ⩾5 in 257 (16.1%), 315 (19.8%), 343
(21.5%), 296 (18.6%) and 382 (24.0%), respectively. The largest
household had 21 participants surveyed. The median number of
household members was 3 (IQR: 2–4). There were 1433 (90.0%)
households that had no members who tested anti-HCV+, 130
(8.2%) had one person who tested anti-HCV+, and 30 (1.8%)
households had ⩾2 test anti-HCV+. The greatest number of per-
sons testing anti-HCV+ in a household was 4.
Individual-level analyses
In individual-level analyses, the proportion of anti-HCV+ people
decreased with an increasing socio-economic score (OR 0.69 (95%
CI 0.62–0.77)) (Fig. 1 and Table 1). This effect persisted among
both rural residents (OR 0.76 (95% CI 0.66–0.88)) and urban resi-
dents (OR 0.76 (95% CI 0.61–0.95)) (Fig. 1). The combined
Fig. 1. The proportion of hepatitis C virus antibody
(anti-HCV) positive individuals by socio-economic score
(higher score is more affluent), for all participants
(with 95% confidence interval), urban participants and
rural participants.
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number of medical exposures was positively associated with
anti-HCV prevalence (continuous OR per additional medical
exposure 1.31 (95% CI 1.17–1.46)) (Fig. 2). The effect was stron-
ger for rural than urban residents: ORs 1.37 (95% CI 1.21–1.55)
and 1.16 (95% CI 0.92–1.46), respectively.
Table 1 shows the aOR of a household member being
anti-HCV+ if another member of that household is anti-HCV+
3.19 (95% CI 2.25–4.50). Living in a rural dwelling was also
positively associated with being anti-HCV+ (aOR 1.57 (95% CI
1.02–2.42)), as was living in the south (aOR 2.60 (95% CI 1.75–
3.87)), age (aOR 1.02 (95% CI 1.01–1.03)), having ever used
opium/bhuki (aOR 2.85 (95% CI 1.71–4.76)) and being shaved
by a barber (aOR 1.78 (95% CI 1.22–2.60)). Ever having drank
alcohol was negatively associated with being anti-HCV-positive,
aOR 0.56 (95% CI 0.38–0.84).
Supplementary Table S1 gives a similar analysis to that pre-
sented in Table 1 but with HCV RNA positivity as the endpoint.
The results of this analysis are similar to those in Table 1, except
shaving at a barber (OR 1.45 (95% CI 0.97–2.18)) and having ever
been incarcerated (OR 2.54 (95% CI 0.97–6.63)) were not asso-
ciated with HCV RNA in single variable analyses. In multivariable
analyses having ever had a motor vehicle accident (aOR 1.61 (95%
CI 1.04–2.50)) was positively associated with HCV RNA positiv-
ity, which was not the case in the analysis with anti-HCV positiv-
ity as the outcome. The association between being HCV
RNA-positive and another member of the household being
HCV RNA-positive was very strong (aOR 3.88 (95% CI
2.56–5.89)), as was the association with socio-economic status
score (aOR 0.67 (95% CI 0.57–0.78)), and the associations with
living in the south (aOR 2.64 (95% CI 1.64–4.26)) and having
ever used opium/bhuki (aOR 3.02 (95% CI 1.67–5.48)).
Simulations
Using the same household size distribution found in the survey,
1000 simulations were conducted, with anti-HCV+ persons ran-
domly distributed among households. The simulations resulted
in a median of 14 (IQR: 11–16) households with ⩾2 members
testing anti-HCV+. Figures 3 shows that none of the 1000
simulations had 30 households with ⩾2 anti-HCV+ members
(P < 0.001).
We compared the distribution of the number of anti-HCV+
persons from each village from the survey with the average num-
ber of persons testing positive across 1000 random simulations.
We found a greater proportion of villages surveyed had multiple
persons anti-HCV+ than in the simulations. For example, 31 of
Table 1. Logistic regression odds ratios (95% confidence intervals) of hepatitis
C virus antibody positivity by individual characteristics (N = 5543 individuals)
Odds ratio (95% CI) for having
anti-HCV
Variable Unadjusted Adjusteda
Another member of
household anti-HCV+
4.53 (3.28–6.27) 3.19 (2.25–4.50)
Living in rural dwelling 3.01 (2.07–4.39) 1.57 (1.02–2.42)
Living in the south 3.25 (2.23–4.73) 2.60 (1.75–3.87)
Age (years) 1.03 (1.02–1.03) 1.02 (1.01–1.03)
Male 1.28 (0.94–1.73)
Medical risks
Ever had surgery 1.54 (1.14–2.09)
Ever had a medical
procedure
2.20 (1.23–3.92)
Ever had a dental
procedure
1.62 (1.20–2.19)
Had a medical injection in
the last 6 months
1.48 (1.09–2.01)
Ever had a streptomycin
injection
2.40 (1.01–5.72)
Ever received blood 1.96 (1.21–3.18)
Ever been hospitalised 1.43 (1.05–1.95)
Medical risk scorea 1.31 (1.18–1.46) 1.17 (1.02–1.33)a
Socio-economic indicators
Receiving water through a
tube well
2.25 (1.66–3.04)
Certified healthcare 0.53 (0.37–0.75)
Kacha (less solid) vs. pucca
house (more solid)
1.32 (0.83–2.10)
Household income (rupees)
0–10 000 1
10 001–20 000 0.74 (0.52–1.05)
>2000 0.58 (0.36–0.92)
Education level
None/primary 1
Middle/secondary 0.70 (0.51–0.96)
Graduate 0.21 (0.10–0.46)
Socio-economic status
scorea
0.69 (0.62–0.77) 0.75 (0.66–0.86)a
Drugs (ever taken)
Ever drank alcohol 0.62 (0.44–0.88) 0.56 (0.38–0.84)
Ever used opium/bhuki 5.06 (3.25–7.90) 2.85 (1.71–4.76)
Ever smoked tobacco 1.21 (0.63–2.32)
Social risks
Have a tattoo 1.54 (0.98–2.44)
Use barbers 1.52 (1.08–2.14) 1.78 (1.22–2.60)
Have body piercings 0.84 (0.53–2.85)
(Continued )
Table 1. (Continued.)
Odds ratio (95% CI) for having
anti-HCV
Variable Unadjusted Adjusteda
Other variables
Ever been incarcerated 2.70 (1.20–6.08) 1.42 (0.58–3.46)
Ever had a motor vehicle
accident
1.77 (1.25–2.48) 1.33 (0.92–1.95)
aFor power only the combined socio-economic status score variable was included rather
than the socio-economic variables, and similarly only the combined medical risk score from
the individual medical risk variables. All other variables that were associated with anti-HCV
in the single variable analysis were then included in the multivariable analysis.
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the 1000 simulated datasets had 10 villages with ⩾6 infections, the
number observed in the survey data (P = 0.03; Fig. 4).
Household-level analyses
As household size increased, the number of members in the
household testing anti-HCV+ increased (Table 2). The number
of members testing anti-HCV+ in the household was also asso-
ciated with living in rural areas and living in Punjab’s south.
Households with a higher proportion of members that had
received a medical injection in the last 6 months were more likely
to have more anti-HCV+ members. Select indicators of lower
S-ES, including receiving water from a tube well, lower
educational level and receiving healthcare from an uncertified/
alternative provider, were associated with a greater number of
household members testing anti-HCV+, as was a lower S-ES
score. The proportion of members of the household that had
ever used opium or bhuki was also associated with having more
anti-HCV+ members.
The associations between household-level variables and the
number of anti-HCV+ household members (0, 1 or ⩾2) are
shown in Table 3. In models only adjusted for the number of
household members, the variables associated with a greater num-
ber of anti-HCV+ members in the household were: living in a
rural area, living in south Punjab, a higher proportion of the
household having had a medical injection in the last 6 months,
Fig. 2. The proportion of hepatitis C virus antibody
(anti-HCV) positive individuals by medical risk score,
for all participants (with 95% confidence interval),
urban participants and rural participants.
Fig. 3. The distribution of the number of households
with two or more hepatitis C virus antibody (anti-HCV)
positive members in the 1000 simulated datasets
assuming HCV randomly distributed, compared to the
observed number of households with two or more mem-
bers with HCV (the dashed line).
Epidemiology and Infection 5
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268819001705
Downloaded from https://www.cambridge.org/core. University of Bristol Library, on 26 Nov 2019 at 12:41:16, subject to the Cambridge Core terms of use, available at
receiving water through a tube well, a higher proportion having
ever taken opium/bhuki and a higher proportion having ever
been incarcerated. Conversely, a higher household income, educa-
tion level, proportion of the household with certified healthcare
and a higher mean S-ES were all associated with a fewer number
of members in the household testing anti-HCV+. A model
adjusted for multiple variables found that several factors were
independently associated with an increase in the number of
household members testing anti-HCV+: more members living
in a household, living in south Punjab, a lower mean S-ES and
a higher proportion of household members having ever used
opium or bhuki. The proportionality of odds assumption test
did not find strong evidence against this assumption (P = 0.093).
Screening probabilities
The survey results translate to 13.0% (n = 120) of 926 households
surveyed in Punjab’s south containing someone anti-HCV+ and
2.9% (n = 27) of these having ⩾2 anti-HCV+ members. These
numbers increase to 19.1% and 4.4%, respectively, for the 230
households surveyed in the south that also had a lower S-ES
score (⩽3). For the north, 6.0% of the 667 households surveyed
contained someone anti-HCV+, which increased to 9.2% when
limited to the 164 households with a lower S-ES score. Of the
194 households surveyed with ⩾1 member that uses either
bhuki or opium, 26.3% had one anti-HCV+ member and 9.8%
had ⩾2 anti-HCV+ members.
Discussion
In Punjab, India, anti-HCV+ individuals cluster within house-
holds and within villages, with higher prevalence in the south
than the north. The number of anti-HCV+ household members
was positively associated with the number of household residents,
lower S-ES and greater use of opium or bhuki in these house-
holds. In single variable analyses only adjusted for the number
of household members, anti-HCV status was positively associated
with the average number of medical injections received in the last
6 months, the proportion of the household that had been incar-
cerated, as well as socio-economic markers such as using an
uncertified healthcare provider, or receiving water from a tube
well. These findings help to elucidate HCV infection in Punjab
and could guide prevention and screening strategies for the state-
wide care and treatment programme [11].
HCV infection is not evenly distributed geographically [7].
Reasons for south Punjab’s higher HCV prevalence are uncertain
but could be due to poorer infection control practices, more syr-
inge re-use or unreported IDU.
Taking opium or bhuki should not transmit HCV because they
are not injected. However, they were strongly related with
anti-HCV positivity, possibly indicating they are proxy markers
for IDU. Stigma may cause under-reporting of IDU, with the pro-
portion reporting ever injecting drugs lower than recently esti-
mated in Punjab [18]. PWID may be under-represented in
household surveys because they are more likely to be homeless
or imprisoned [13, 21]. Although some evidence suggests
opium/bhuki use could be associated with heroin use [19], its
use as a marker of IDU needs further study to understand the val-
idity of using such proxies.
Household anti-HCV positivity was inversely associated with
the household’s S-ES. Lower-income households may lack access
to higher quality healthcare, leading to a greater risk of iatrogenic
HCV transmission.
Literature comparison
Anti-HCV positivity clustering within households could be due to
intra-familial transmission between household members or by
household members being exposed to common risks outside the
house, such as sharing a doctor [22]. Our study cannot deter-
mine if households with multiple persons testing anti-HCV+
acquired their infection from exposures within or outside the
household [23]. Other studies have looked at HCV clustering
at the household/family level, with some in low prevalence
countries finding an association [24, 25] or not [26–28], while
others in higher prevalence countries [5] found associations.
One study found intraspousal HCV transmission more com-
mon than other intrafamilial transmission [29]. The association
found between low S-ES and anti-HCV positivity has been
demonstrated previously, including in Thailand [30], the
Fig. 4. Histograms showing the number of hepatitis C virus antibody (anti-HCV) positive members of each village/ward (left panel: observed, right panel: average of
1000 simulations).
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Netherlands [31] and Pakistan [32, 33]. Utilizing advanced
molecular diagnostics, such as deep-gene sequencing, could bet-
ter define transmission patterns within households, elucidating
risks and guiding prevention efforts.
Strengths and limitations
This study analysed data from a large serosurvey, covering diverse
areas of Punjab. However, the sampling frame used census data,
which may underestimate the state’s anti-HCV prevalence as it
Table 2. Comparing the mean characteristics of households (N = 1593) with 0, 1 and ⩾2 members testing positive for hepatitis C virus antibody, respectively
Number of members anti-HCVa positive
in a household
0 1 2+
Number of households
Test for differencesbCharacteristic 1433 130 30
Mean number of members in the household 3.32 4.72 5.67 P < 0.001
Mean proportion in rural dwellings 0.60 0.79 0.87 P < 0.001
Mean proportion living in the south 0.56 0.72 0.90 P < 0.001
Mean age 38 37 40 P = 0.441
Mean proportion male 0.45 0.48 0.51 P = 0.320
Medical risks
Mean proportion that have had surgery 0.44 0.41 0.49 P = 0.497
Mean proportion that have a medical procedure 0.04 0.03 0.05 P = 0.620
Mean proportion that have had a dental procedure 0.41 0.40 0.47 P = 0.571
Mean proportion that have had a medical injection in the last 6 months 0.34 0.41 0.39 P = 0.049
Mean proportion that have had a streptomycin injection 0.01 0.02 0.01 P = 0.578
Mean proportion that have received blood 0.07 0.09 0.07 P = 0.537
Mean proportion that have been hospitalised 0.55 0.54 0.58 P = 0.795
Mean medical risk score 1.9 1.9 2.1 P = 0.479
Socio-economic indicators
Mean proportion receiving water from a tube well 0.32 0.45 0.68 P < 0.001
Mean proportion with certified healthcarec 0.40 0.27 0.23 P < 0.001
Mean proportion in a kacha house (less solid structure) 0.10 0.17 0.04 P = 0.022
Household incomed 0.62 0.50 0.47 P = 0.133
Education leveld 1.76 1.64 1.63 P = 0.015
Mean socio-economic status score 4.2 3.7 3.5 P < 0.001
Drugs (ever taken)
Mean proportion that have ever drunk alcohol 0.33 0.34 0.30 P = 0.827
Mean proportion that have ever used opium/bhukie 0.03 0.07 0.16 P < 0.001
Mean proportion that have ever smoked tobacco 0.05 0.03 0.05 P = 0.257
Social risks
Mean proportion with tattoo 0.09 0.10 0.08 P = 0.588
Mean proportion using barber 0.19 0.21 0.25 P = 0.374
Mean proportion with body piercings 0.56 0.54 0.49 P = 0.370
Other variables
Mean proportion that have ever been incarcerated 0.01 0.02 0.03 P = 0.324
Mean proportion that have ever had a motor vehicle accident 0.19 0.20 0.27 P = 0.286
aHepatitis C antibody-positive.
bANOVA test (single variable).
cReceiving healthcare from a certified healthcare provider (as opposed to an uncertified/alternative health care provider).
dEducation and household income are using an ordinal variable where lower categories indicate lower education or income.
eBhuki is an intoxicating wild grass that is ingested.
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excludes homeless populations, new arrivals, prisons and new
peri-urban slums. We were unable to correct the overall preva-
lence estimate to account for the prevalence among these popula-
tions due to a lack of data. A cross-sectional serosurvey asking
about recent behaviours cannot accurately capture the effect of
lifetime medical exposures and injections with contaminated nee-
dles, which are important factors associated with HCV prevalence
in India, South Asia and globally [15, 34]. The receipt of medical
injections is very common in this population, with around 35% of
the sample having received one in the previous 6 months. This
Table 3. Multivariable ordered logistic regression odds ratios (95% confidence intervals) of hepatitis C virus antibody positivity by household characteristics
(N = 1593 households)
Odds ratio (95% CI) for having 0, 1 or ⩾2 members in the household
with anti-HCVe
Adjusteda Fully adjusted, backwards eliminationb
Number of members in the household 1.31 (1.22–1.40)c 1.38 (1.28–1.48)
Living in rural dwellings 2.88 (1.87–4.43)c
Living in the south 3.29 (2.14–5.04)c 3.15 (1.98–5.02)
Mean age 1.01 (1.00–1.02)
Proportion male 1.83 (0.90–3.72)
Medical risks
Proportion that have had surgery 0.87 (0.47–1.61)
Proportion that have had a medical procedure 1.05 (0.30–3.66)
Proportion that have had a dental procedure 1.13 (0.67–1.91)
Proportion that have had a medical injection in the last 6 months 2.25 (1.30–3.88)c
Proportion that have had a streptomycin injection 1.50 (0.20–11.11)
Proportion that have received blood 2.21 (0.82–5.93)
Proportion that have been hospitalised 1.04 (0.60–1.80)
Mean medical risk score 1.16 (0.95–1.43)
Socio-economic indicators
Receiving water through a tube well 1.94 (1.33–2.84)
Proportion with a certified healthcare provider (vs. uncertified/alternative) 0.34 (0.20–0.58)
Kacha (less solid) vs pucca house (more solid) 1.77 (1.05–2.98)
Household incomed 0.64 (0.49–0.85)
Education leveld 0.51 (0.36–0.74)
Mean socio-economic status 0.61 (0.51–0.74)c 0.63 (0.55–0.74)
Drugs (ever taken)
Proportion that have ever drank alcohol 0.66 (0.35–1.24)
Proportion that have ever used opium/bhuki 26.68 (9.05–78.62)c 16.69 (5.46–51.02)
Proportion that have ever smoked tobacco 0.36 (0.06–2.16)
Social risks
Proportion with a tattoo 1.67 (0.63–4.44)
Proportion using barbers 1.46 (0.69–3.07)
Proportion with body piercings 0.60 (0.31–1.17)
Other variables
Proportion that have ever been incarcerated 6.01 (1.11–32.59)c
Proportion that have ever had a motor vehicle accident 1.74 (0.89–3.39)
aAdjusted for the number of members in the household.
bVariables that were associated with HCV in the analyses only adjusting for number of members in the household (the second column), denoted c, were entered into a backwards elimination
model, with the third column presenting the variables that were selected by the backwards elimination model (for power only the mean socio-economic status was included in the selection
model rather than the individual socio-economic variables).
cVariables entered into the backwards elimination model.
dEducation and household income are using ordinal variables where lower categories indicate lower education or income.
eHepatitis C antibodies.
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cross-sectional serosurvey is limited to identifying behaviours
associated with prevalent, rather than recent infections, and was
likely subject to recall and social desirability bias, particularly
affecting the reported prevalence of ever having injected drugs.
The proxy measures used possibly captured an effect other than
IDU such as low socio-economic status, which is itself a proxy
measure, possibly of utilizing unsafe healthcare providers [14].
The negative association between having ever drank alcohol and
being anti-HCV-positive is probably a proxy measure for S-ES,
maybe caste or religion [35]. This study can only estimate associa-
tions, which may be subject to unmeasured confounding. The
simulation analyses may be limited by high heterogeneity in
anti-HCV prevalence between districts. We were unable to further
stratify the household analyses by the number of anti-HCV+
members in each household due to a lack of households contain-
ing ⩾3 multiple infected persons. Treatment for HCV in Punjab
before this survey was administered was rare and would have been
unlikely to affect the anti-HCV or RNA prevalence in the study
population.
Implications
This study found anti-HCV+ persons clustered in households and
in villages in Punjab, India. This is an important consideration for
the recently launched treatment programme in Punjab aiming to
eliminate hepatitis C [1, 15]. Officials should consider testing
whole families when one family member tests positive for
anti-HCV or HCV RNA. This may achieve a higher yield than
general testing. Similarly, the reasons for clustering of anti-HCV+
persons in villages could be from sharing a healthcare provider,
or barber or high IDU prevalences in some villages. Further
research is required to understand why infection clusters at the
village and household levels. In households, there is a range of
possible factors, including sexual transmission, sharing razors or
using the same barber or healthcare provider with poor infection
control practices [36].
Understanding these factors will help planners implement
interventions that could prevent HCV transmission in this con-
text and are valuable for initiatives linking those infected to
care. For those designing hepatitis C testing and prevention pro-
grammes in Punjab, this study provides valuable information,
including that households with lower S-ES and households in
the south tend to have more anti-HCV+ members. This indicates
these groups may benefit from targeted testing and treatment.
Furthermore, in Punjab’s south, there is approximately a 13%
chance that any household screened will yield someone
anti-HCV+. This probability increases to roughly 17% for poorer
households. Households that have a member reporting opium or
bhuki use have over 25% chance of a household member having
HCV infection. Information on HCV transmission risks and how
to sterilise medical equipment should be targeted to medical prac-
titioners, particularly in high prevalence areas. This could reduce
HCV transmission in Punjab, which combined with scaled-up
treatment should reduce the high HCV prevalence.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0950268819001705.
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